Table 2.
Comparison of idasanutlin trial patients with and without TP53 mutations
| Characteristic | Presence of TP53 mutation | |
|---|---|---|
| No (n = 7) | Yes (n = 5) | |
| Age, y | ||
| Mean ± SD | 57.1 ± 13.50 | 63.9 ± 13.74 |
| Median | 61.7 | 65.6 |
| Range | 32.8, 69.5 | 49.0, 83.8 |
| Initial diagnosis, n (%) | ||
| Essential thrombocythemia | 1 (14.3) | 0 (0.0) |
| PV | 6 (85.7) | 5 (100.0) |
| Sex, n (%) | ||
| Female | 4 (57.1) | 3 (60.0) |
| Male | 3 (42.9) | 2 (40.0) |
| Disease duration (before study), mo | ||
| Mean ± SD | 58.9 ± 32.43 | 58.6 ± 54.58 |
| Median | 60.9 | 43.9 |
| Range | 14.9, 94.2 | 21.0, 154.3 |
| HU intolerance/resistance, n (%) | ||
| HU-intolerant | 5 (71.4) | 3 (60.0) |
| HU-resistant | 1 (14.3) | 1 (20.0) |
| No exposure | 1 (14.3) | 1 (20.0) |
| Planned dose cohort, n (%) | ||
| 100 mg | 5 (71.4) | 1 (20.0) |
| 150 mg | 2 (28.6) | 4 (80.0) |
| Cycles, n | ||
| N | 5 | 12 |
| Mean ± SD | 9.3 ± 3.20 | 14.4 ± 4.28 |
| Median | 9 | 14 |
| Range | 5.0, 14.0 | 9.0, 20.0 |
| Duration on study, wk | ||
| Mean ± SD | 52.4 ± 38.36 | 77.7 ± 25.86 |
| Median | 36.3 | 85.1 |